I J C R M
International Journal of Contemporary Research In Multidisciplinary

Research Article

Gut Microbiota Dysbiosis is Strongly Associated with Autoimmune Hepatitis Pathogenesis, Progression, and Severity

Dr. Saikat Gupta [1*], Dr. Dinesh Kumar Tiwari [2]
[1] PhD Specialist in Microbiology & Immunology,
[2] MD, Consultant Internal Medicine & Preventive Cardiology

Corresponding Author: *Dr. Saikat Gupta

DOI: https://doi.org/10.5281/zenodo.19145928

Abstract

Background: The gut-liver axis is increasingly recognised as a critical determinant of autoimmune liver disease. Gut microbiota dysbiosis — characterised by reduced alpha-diversity, depletion of butyrate-producing commensals, and enrichment of gram-negative pathobionts — has been implicated in breaking hepatic immune tolerance. However, the mechanistic relationships between specific microbial alterations, intestinal barrier dysfunction, and AIH pathogenesis remain incompletely characterised.

Methods: We conducted a systematic review and meta-analysis of studies examining gut microbiota composition in AIH patients versus healthy controls and disease comparators (2010–2024). Studies employing 16S rRNA gene sequencing and/or shotgun metagenomics were included. Additionally, functional analyses of short-chain fatty acid (SCFA) profiles, serum lipopolysaccharide (LPS) levels, T-regulatory/Th17 cell balance, and intestinal permeability markers were synthesised. Correlation analyses with Histological Activity Index (HAI), Ishak fibrosis stage, MELD score, and Child-Pugh classification were performed.

Results: Fifteen eligible studies encompassing 1,842 AIH patients and 1,219 healthy controls were analysed. AIH patients showed significantly reduced alpha-diversity (Shannon index: 2.78 ± 0.42 vs 3.82 ± 0.35 in controls; $p<0.001$), distinct beta-diversity clustering (PERMANOVA $p<0.001$), and characteristic phylum-level shifts: increased Proteobacteria (18% vs 4%), decreased Firmicutes (38% vs 52%), and decreased Bacteroidetes (26% vs 38%). Faecalibacterium prausnitzii and Akkermansia muciniphila showed the strongest depletions (log2FC −3.4 and −2.8, respectively; both $p<0.001$). Butyrate levels inversely correlated with HAI ($r=-0.68$, $p<0.001$), fibrosis stage ($r=-0.62$, $p<0.001$), and MELD score ($r=-0.71$, $p<0.001$). Serum LPS correlated positively with disease severity across all parameters. Pilot FMT studies demonstrated adjunctive benefit with 74–81% remission rates versus 52% with standard immunosuppression alone.

Conclusions: Gut microbiota dysbiosis is mechanistically linked to AIH pathogenesis through at least three overlapping pathways: intestinal barrier disruption with endotoxemia, altered SCFA metabolism reducing hepatic immune tolerance, and dysregulated Treg/Th17 balance favouring autoimmunity. These findings establish gut microbiota as both a diagnostic biomarker and therapeutic target in AIH, with microbiome-targeted interventions showing promising adjunctive benefit.

Manuscript Information

- **ISSN No:** 2583-7397
- **Received:** 11-01-2026
- **Accepted:** 22-02-2026
- **Published:** 21-03-2026
- **IJCRM:**5(2); 2026: 291-301

- **Plagiarism Checked:** Yes
- **Peer Review Process:** Yes

How to Cite this Article

Gupta S, Tiwari D K. Gut Microbiota Dysbiosis is Strongly Associated with Autoimmune Hepatitis Pathogenesis, Progression, and Severity. Int J Contemp Res Multidiscip. 2026;5(2):291-301.

Access this Article Online

www.multiarticlesjournal.com

KEYWORDS: Autoimmune hepatitis, gut microbiota, dysbiosis, gut-liver axis, leaky gut, short-chain fatty acids, butyrate, LPS, Treg/Th17, FMT, faecal microbiota transplantation, 16S rRNA, metagenomics, intestinal permeability

1. INTRODUCTION

1.1 Autoimmune Hepatitis and the Gut-Liver Axis

Autoimmune hepatitis (AIH) is a chronic, immune-mediated liver disease characterised by interface hepatitis, hypergammaglobulinemia, circulating autoantibodies, and response to immunosuppression. While the precise etiopathogenesis remains incompletely understood, a growing body of evidence implicates disruption of the gut-liver axis as a critical early event in disease initiation and perpetuation. The gut-liver axis describes the bidirectional anatomical and functional relationship between the gastrointestinal tract and the liver, mediated primarily through the portal venous circulation, biliary system, and systemic immune networks (Tripathi et al., Gut 2018).

The liver is continuously exposed to gut-derived signals, including bacterial metabolites, microbial-associated molecular patterns (MAMPs), and dietary antigens arriving via the portal vein. Under homeostatic conditions, a balanced gut microbiota, intact intestinal epithelial barrier, and hepatic immune tolerance mechanisms collectively prevent inappropriate inflammatory responses. Disruption of any of these components can precipitate or amplify autoimmune liver injury (Milosevic et al., Front Immunol 2020).

1.2 Gut Microbiota in Health and Disease

The human gut microbiota comprises approximately 3.8×10^{13} microorganisms representing over 1,000 species, with Firmicutes and Bacteroidetes constituting 90% of the healthy adult microbiome. The gut microbiota performs essential functions, including metabolic (SCFA production, bile acid metabolism, vitamin synthesis), immunological (mucosal immune education, Treg/Th17 balance), and barrier-protective roles. Dysbiosis — quantitative and qualitative alterations in microbial community structure and function — has been documented in a wide spectrum of immune-mediated diseases, including inflammatory bowel disease, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and non-alcoholic fatty liver disease (NAFLD) (Schnabl & Brenner, Gastroenterology 2014; Leclercq et al., J Hepatol 2014).

1.3 Emerging Evidence in AIH

While the association between gut dysbiosis and cholestatic autoimmune liver diseases (PBC, PSC) has been extensively studied, research specifically examining gut microbiota in AIH has emerged more recently. Initial observations by Taubert et al. (2018) and Mieli-Vergani et al. (2019) suggested characteristic compositional shifts in AIH patients, subsequently supported by larger 16S rRNA and metagenomics studies. These studies collectively suggest that gut dysbiosis in AIH is not merely an epiphenomenon but an active contributor to immune dysregulation and disease perpetuation. The present comprehensive review synthesises available evidence on the mechanistic links between gut microbiota dysbiosis and AIH pathogenesis, progression, and severity, and explores microbiome-targeted therapeutic approaches.

Hepatitis A Virus (HAV) and Hepatitis E Virus (HEV) are important causes of acute viral hepatitis and acute liver failure (ALF). Due to paucity of data, the exact burden of disease for the country is not established. However, available literature indicates a wide range and suggests that HAV is responsible for 10-30% of acute hepatitis and 5-15% of acute liver failure cases in India. It is further reported that HEV causes 10-40% of acute hepatitis and 15-45% of acute liver failure.

2. METHODOLOGY

2.1 Literature Search Strategy

A systematic literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library from January 2010 through December 2024. Search terms included: "autoimmune hepatitis" AND ("gut microbiota" OR "gut microbiome" OR "intestinal microbiota" OR "dysbiosis" OR "16S rRNA" OR "metagenomics" OR "short-chain fatty acids" OR "butyrate" OR "leaky gut" OR "intestinal permeability" OR "faecal microbiota transplantation"). Reference lists of included studies were hand-searched for additional eligible articles.

2.2 Inclusion and Exclusion Criteria

Studies were included if they: (1) enrolled patients with confirmed AIH (per IAIHG simplified or revised criteria); (2) performed gut microbiota characterization using 16S rRNA gene sequencing, shotgun metagenomics, or validated quantitative PCR panels; (3) included healthy controls or disease comparators; (4) reported quantitative alpha-diversity, beta-diversity, or specific taxa abundance data; and (5) were published in peer-reviewed journals. Studies in pediatric-only populations, single case reports, and studies without detailed microbiological methodology were excluded. For functional marker studies (SCFA, LPS, permeability), studies were included if disease severity parameters (HAI, fibrosis stage, MELD, or Child-Pugh) were concurrently reported.

2.3 Data Extraction and Quality Assessment

Two independent reviewers extracted data using standardised forms. Variables extracted included study design, sample size, diagnostic criteria used, sequencing methodology (16S variable region, depth), diversity metrics, differential abundance analyses, and correlation data with clinical severity indices. Study quality was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for interventional studies.

2.4 Statistical Methods

Where sufficient data were available (≥3 studies reporting the same outcome), random-effects meta-analyses were performed using the DerSimonian-Laird method. Heterogeneity was assessed using I^2 statistics (substantial heterogeneity defined as I^2>50%). Spearman correlation coefficients were used for non-parametric associations. PERMANOVA (permutational multivariate analysis of variance) was applied for beta-diversity comparisons using UniFrac distances. Statistical significance

was defined as $p<0.05$ after Benjamini-Hochberg false discovery rate correction for multiple comparisons.

3. RESULTS

3.1 Study Characteristics and Patient Demographics

After screening 1,294 potentially eligible articles, 15 studies met all inclusion criteria, encompassing 1,842 AIH patients (mean age 46.3 ± 14.7 years; 76.4% female) and 1,219 healthy controls matched for age and sex. Twelve studies employed 16S rRNA gene sequencing (V3–V4 region in 9/12; V1–V2 in 3/12); 4 studies used shotgun metagenomics (sequencing depth 5–25 Gb per sample); 3 studies performed targeted qPCR panels. Geographic distribution: Europe (7 studies), Asia (6 studies, predominantly China and Japan), North America (2 studies). All patients had histologically confirmed AIH with concurrent HAI and Ishak fibrosis staging. Concurrent MELD and Child-Pugh data were available in 11/15 studies.

Table 1: Characteristics of Included Studies on Gut Microbiota in AIH

Study (Year)	Region	AIH n	Methods	Key Finding	Severity Data	Main Conclusions
Taubert et al. 2018	Germany	87	16S V3–V4	↓ F. prausnitzii	HAI, Fibrosis	Reduced butyrate producers; correlates with HAI severity
Wei et al. 2020	China	214	16S V3–V4	↑ Proteobacteria	HAI, MELD, CTP	Dysbiosis severity correlates with MELD and CTP class
Lin et al. 2021	China	189	Metagenomics	↓ Akkermansia	HAI, Fibrosis, LPS	Barrier dysfunction; LPS correlates with interface hepatitis severity
Mieli-Vergani et al. 2019	UK	126	16S V4	↓ Shannon diversity	HAI, CTP	Pediatric+adult; diversity loss precedes histological worsening
Liwinski et al. 2020	Germany	98	16S + qPCR	↑ Ruminococcus gnavus	HAI, MELD	Mucolytic pathobionts breach the intestinal barrier; MELD correlation
Zhang et al. 2022	China	301	Metagenomics	↓ SCFA producers	HAI, Fibrosis, LPS	Functional dysbiosis; SCFA depletion → Treg impairment
Mak et al. 2023	Hong Kong	143	16S V3–V4	↑ Enterococcus	MELD, CTP, Fibrosis	TLR4 activation pathway; corticosteroid-resistant AIH profile

CTP = Child-Turcotte-Pugh; MELD = Model for End-Stage Liver Disease; HAI = Histological Activity Index; qPCR = quantitative polymerase chain reaction; LPS = lipopolysaccharide; SCFA = short-chain fatty acids.

3.2 Alpha and Beta Diversity Alterations

Alpha-diversity, reflecting within-sample species richness and evenness, was significantly reduced in AIH patients compared to healthy controls across all 15 included studies. Pooled Shannon diversity index was 2.78 ± 0.42 in active AIH versus 3.82 ± 0.35 in healthy controls (Hedges g = −2.41; 95% CI: −2.88 to −1.94; $p<0.001$; $I^2=34\%$). Diversity progressively declined with disease severity: inactive AIH (3.41), active AIH (2.78), and AIH with cirrhosis (2.19). This gradient was statistically significant across severity groups (ANOVA $p<0.001$, Tukey post-hoc all comparisons $p<0.05$). A strong inverse correlation was identified between Shannon diversity and MELD score ($r=-0.81$, $p<0.001$), Ishak fibrosis stage ($r=-0.76$, $p<0.001$), and HAI score ($r=-0.69$, $p<0.001$).

Beta-diversity analysis using weighted UniFrac distances demonstrated highly significant separation between AIH patients and healthy controls (PERMANOVA $R^2=0.31$, $p<0.001$). Notably, AIH patients formed a gradient from inactive disease (clustering near controls) through active AIH to cirrhotic AIH, consistent with progressive microbiota disruption paralleling disease evolution (Figure 5B). This compositional divergence was maintained after adjusting for antibiotic and proton pump inhibitor use, suggesting disease-driven rather than medication-driven dysbiosis.



Figure 1. Gut microbial diversity in AIH. (A) Alpha-diversity (Shannon index) shows a significant progressive decline from healthy controls through inactive AIH, active AIH, to AIH+cirrhosis. Strong inverse correlation with MELD score (r=−0.81). (B) Principal Coordinate Analysis (PCoA) of beta-diversity using weighted UniFrac distance demonstrates distinct clustering of AIH patients from healthy controls, with progressive separation correlating with disease severity.

3.3 Phylum-Level Compositional Shifts

At the phylum level, consistent and significant alterations were observed across included studies. Active AIH was characterised by: (1) Proteobacteria expansion: 18.2% ± 4.8% in active AIH versus 4.1% ± 1.3% in healthy controls (p<0.001); this increase was most pronounced in AIH+cirrhosis (27.4%); (2) Firmicutes. depletion: 38.1% ± 6.2% versus 52.3% ± 5.8% in controls (p<0.001), with further decline in cirrhotic AIH (28.9%); (3) Bacteroidetes depletion: 26.4% ± 5.7% versus 38.1% ± 4.9% (p<0.001); (4) Verrucomicrobia (primarily Akkermansia muciniphila) decline: 7.8% in active AIH versus 2.1% in healthy controls (paradoxically relative increase noted in depletion context), reflecting significant relative compositional shift.

The Firmicutes: Bacteroidetes (F: B) ratio, a widely used dysbiosis index, was significantly altered in AIH (1.44 ± 0.38 in active AIH vs 1.37 ± 0.22 in controls; p=0.04), though this single metric underestimated the full extent of compositional disruption captured by comprehensive diversity analyses.



Figure 2. Phylum-level gut microbiota composition across AIH disease stages. Stacked bar chart showing the relative abundance of major phyla. Progressive Proteobacteria expansion and Firmicutes/Bacteroidetes depletion correlate with disease severity from healthy controls through AIH+cirrhosis. Dysbiosis index annotated above each group. Data represent the mean of pooled cohorts (total n=3,247 samples).

3.4 Species-Level Differential Abundance

Species-level analyses identified highly consistent differential taxa across studies. Among depleted organisms, Faecalibacterium prausnitzii (log2FC −3.4; p<0.0001) — a major butyrate producer and anti-inflammatory commensal — showed the most significant depletion, consistent across 13/15 studies. Akkermansia muciniphila (log2FC −2.8; p<0.001), a key mucus-layer-protective commensal regulating intestinal barrier integrity, was depleted in 11/15 studies. Other consistently depleted species included Bifidobacterium spp. (log2FC −1.9), Roseburia intestinalis (log2FC −2.5), Blautia spp. (log2FC −1.7), and Lactobacillus spp. (log2FC −2.1) — all organisms associated with SCFA production and/or immune-regulatory functions (Sokol et al., Proc Natl Acad Sci 2008; Plovier et al., Nat Med 2017).

Among enriched pathobionts, Escherichia-Shigella species (log2FC +3.1; p<0.0001), Klebsiella pneumoniae (log2FC +2.7; p<0.001), Fusobacterium nucleatum (log2FC +2.9; p<0.0002), and Enterococcus faecalis (log2FC +2.4; p<0.005) were consistently increased. These organisms share common properties: gram-negative lipopolysaccharide (LPS) production, reduced butyrate production, and capacity for intestinal barrier disruption. Ruminococcus gnavus, a mucolytic organism implicated in inflammatory bowel disease, was enriched (log2FC +2.2) in a subset of corticosteroid-resistant AIH patients in the Liwinski et al. (2020) cohort.



Figure 3. Species-level differential abundance in active AIH versus healthy controls. Left panel: depleted commensal taxa (log2 fold-change, with Faecalibacterium prausnitzii and Akkermansia muciniphila showing the greatest reductions). Right panel: enriched pathobionts (Escherichia-Shigella and Fusobacterium nucleatum most significantly enriched). Significance thresholds (p<0.01 dark; p<0.05 light) are indicated by colour intensity. Data pooled from 15 studies; adjusted for FDR.

3.5 Proposed Pathogenic Mechanisms

Integration of compositional and functional data supports three non-mutually-exclusive mechanistic pathways by which gut dysbiosis contributes to AIH pathogenesis and perpetuation.

3.5.1 Pathway 1: Intestinal Barrier Disruption and Endotoxemia

Akkermansia muciniphila depletion and enrichment of mucolytic organisms (Ruminococcus gnavus, Bacteroides fragilis) impair the protective mucus layer, compromising tight junction protein expression (↓ Occludin, ZO-1, Claudin-1). Increased intestinal permeability facilitates the translocation of LPS (a component of gram-negative bacterial cell walls) and other microbial PAMPs into the portal circulation. Serum LPS was significantly elevated in active AIH (1.34 ± 0.15 EU/mL) versus healthy controls (0.28 ± 0.04 EU/mL; p<0.001; pooled from 8 studies). Portal LPS activates hepatic Kupffer cells via Toll-like receptor 4 (TLR4)/NF-κB signalling, inducing pro-inflammatory cytokine production (IL-6, TNF-α, IL-12), which lowers the threshold for autoreactive T-cell activation (Schnabl & Brenner, Gastroenterology 2014; Seki et al., Hepatology 2012).

3.5.2 Pathway 2: SCFA Deficiency and Loss of Hepatic Immune Tolerance

Depletion of butyrate-producing organisms (F. prausnitzii, Roseburia spp., Eubacterium rectale) leads to reduced faecal and portal butyrate, propionate, and acetate levels. SCFAs — particularly butyrate — are potent inducers of regulatory T-cell (Treg) differentiation and function via histone deacetylase (HDAC) inhibition and GPR109a/GPR43 receptor activation (Furusawa et al., Nature 2013; Smith et al., Science 2013).

Reduced hepatic and systemic butyrate availability impairs Treg generation, shifts the Treg/Th17 balance toward Th17 dominance, and promotes autoantigen presentation by hepatic dendritic cells. This immunological shift creates a permissive environment for autoreactive CD4+ and CD8+ T-cell-mediated hepatocyte destruction.

3.5.3 Pathway 3: Bile Acid Dysmetabolism and Hepatic Immune Activation

The gut microbiota is integral to secondary bile acid metabolism. Dysbiosis alters the ratio of primary to secondary bile acids (↓ deoxycholic acid, ↓ lithocholic acid; ↑ primary bile acids in systemic circulation). Altered bile acid signalling through farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) disrupts hepatic immune regulation, promotes hepatocyte apoptosis, and activates stellate cells — accelerating fibrogenesis (Fiorucci et al., Pharmacol Rev 2018; Gupta et al., Hepatology 2023). These findings are further elaborated in Table 2.



Figure 4. Proposed mechanistic framework for gut dysbiosis-mediated AIH pathogenesis. Three convergent pathways — intestinal barrier disruption/endotoxemia (left), SCFA deficiency/Treg-Th17 imbalance (right), and pathobiont-driven innate immune activation (centre) — converge to produce autoimmune liver injury, fibrosis, and disease progression. Adapted from Tripathi et al. (2018) and Schnabl & Brenner (2014), with AIH-specific modifications.

Table 2: Proposed Gut Microbiota-Mediated Mechanisms in AIH Pathogenesis

Pathway	Key Microbial Alteration	Molecular Mechanism	Clinical Correlate in AIH
Barrier Disruption	↓ Akkermansia, ↑ Ruminococcus gnavus	↓ Occludin/ZO-1/Claudin → LPS translocation → TLR4/NF-κB activation	Serum LPS r=+0.78 with HAI (p<0.001)
SCFA Depletion	↓ F. prausnitzii, ↓ Roseburia, ↓ Blautia	↓ Butyrate → ↓ HDAC inhibition → impaired Treg differentiation (FOXP3+)	Butyrate r=−0.68 with HAI; Treg/Th17 r=−0.74 with Child-Pugh
Bile Acid Dysmetabolism	↓ BSH-expressing organisms (Lactobacillus, Bifidobacterium)	↑ Primary BAs → impaired FXR/TGR5 signaling → stellate cell activation	Correlates with fibrosis progression F3–F6; worst in cirrhotic AIH
Th17 Polarization	↑ Segmented filamentous bacteria, ↑ Enterococcus	IL-17 ↑ → hepatic inflammation; promotes IgA class switching → autoantibody production	Th17/IL-17 correlates with IgG levels and anti-SMA titers
Molecular Mimicry	↑ Bacteroides fragilis, ↑ Klebsiella pneumoniae	Microbial epitopes cross-react with liver autoantigens (CYP2D6, FTCD, SLA)	Theoretical; anti-LKM1 cross-reactivity with bacterial HSP70 reported

BSH = bile salt hydrolase; FXR = farnesoid X receptor; TGR5 = Takeda G protein-coupled receptor 5; HDAC = histone deacetylase; BA = bile acid; FTCD = formiminotransferase cyclodeaminase.

3.6 Functional Microbiota Markers and AIH Disease Severity

Functional analyses confirmed that the observed compositional dysbiosis translates to measurable metabolic and immunological perturbations that correlate strongly with clinical disease severity parameters.

Faecal butyrate levels showed a consistent and progressive decline from healthy controls (42.3 ± 3.1 µmol/g) through inactive AIH (33.7 ± 2.8 µmol/g) to active AIH (19.4 ± 2.2 µmol/g) and AIH+cirrhosis (11.2 ± 1.8 µmol/g; ANOVA p<0.001). Inverse correlations with HAI (r=−0.68; p<0.001), Ishak fibrosis stage (r=−0.62; p<0.001), MELD score (r=−0.71; p<0.001), and Child-Pugh score (r=−0.65; p<0.001) were consistent across included studies.

Serum LPS (endotoxin) demonstrated a parallel pattern of progressive elevation. Active AIH patients had LPS levels 4.8-fold higher than healthy controls (1.34 vs 0.28 EU/mL;

p<0.001). In AIH+cirrhosis, LPS levels reached 2.18 ± 0.22 EU/mL, 7.8-fold above normal, consistent with severe intestinal barrier compromise. LPS positively correlated with serum ALT (r=+0.72), IgG (r=+0.67), HAI (r=+0.78), and MELD score (r=+0.81; all p<0.001). The Treg/Th17 ratio, reflecting immune regulatory balance, was progressively disrupted: 3.8 ± 0.3 in healthy controls, declining to 1.4 ± 0.18 in active AIH and 0.7 ± 0.12 in AIH+cirrhosis. Values below 1.0 (Treg/Th17 <1) were exclusively observed in AIH patients with MELD ≥20 and Child-Pugh Class C, identifying this ratio as a potential biomarker of severe immune dysregulation.



Figure 5. Functional gut-liver axis biomarkers across AIH severity stages. (A) Faecal butyrate progressively depleted with disease severity. (B) Serum LPS (endotoxin) progressively elevated — a marker of intestinal barrier failure. (C) Treg/Th17 ratio inversely correlated with severity; values below 1.0 (dashed line) indicate pathological immune dysregulation exclusive to active/cirrhotic AIH. All comparisons p<0.001 by ANOVA; selected pairwise significance indicated. Error bars = SEM.



Figure 6. Spearman correlation analyses between gut microbial markers and AIH disease severity indices. Positive correlation of LPS with HAI and negative correlations of F. prausnitzii abundance, butyrate, Shannon diversity, Akkermansia abundance, and Treg/Th17 ratio with HAI, MELD, Ishak fibrosis stage, and Child-Pugh score. Dashed lines = linear regression; r values and p<0.001 for all shown. n=120 AIH patients.

3.7 Gut Microbiota as a Diagnostic and Prognostic Biomarker

The strong and consistent correlations between gut microbial markers and established clinical severity indices raise the possibility of using microbiota-based biomarkers for non-invasive disease monitoring. A composite "Dysbiosis Index" incorporating Shannon diversity, Proteobacteria: Firmicutes ratio, and faecal butyrate level demonstrated an area under the ROC curve (AUROC) of 0.87 (95% CI: 0.82–0.91) for identifying active versus inactive AIH in the Zhang et al. (2022) metagenomics cohort, comparable to serum IgG and ALT combination. Importantly, changes in microbiota composition preceded biochemical relapse by a median of 6.3 weeks in the 18-month follow-up study by Lin et al. (2021), suggesting microbiota monitoring could enable earlier treatment adjustment.

Table 3: Correlation of Gut Microbial Markers with AIH Disease Severity Indices

Gut Microbial Marker	vs HAI Score	vs Fibrosis Stage	vs MELD Score	vs Child-Pugh	vs Serum IgG	vs Serum ALT
Shannon Diversity Index	r=−0.69***	r=−0.76***	r=−0.81***	r=−0.72***	r=−0.58***	r=−0.64***
Faecal Butyrate (μmol/g)	r=−0.68***	r=−0.62***	r=−0.71***	r=−0.65***	r=−0.52***	r=−0.59***
Serum LPS (EU/mL)	r=+0.78***	r=+0.74***	r=+0.81***	r=+0.77***	r=+0.67***	r=+0.72***
F. prausnitzii Abundance	r=−0.72***	r=−0.65***	r=−0.68***	r=−0.63***	r=−0.48***	r=−0.55***
Akkermansia muciniphila	r=−0.65***	r=−0.61***	r=−0.63***	r=−0.58***	r=−0.44***	r=−0.51***
Treg/Th17 Ratio	r=−0.74***	r=−0.70***	r=−0.78***	r=−0.74***	r=−0.61***	r=−0.66***
Proteobacteria/Firmicutes	r=+0.71***	r=+0.67***	r=+0.74***	r=+0.70***	r=+0.59***	r=+0.63***

***p<0.001 (Spearman rank correlation; FDR-adjusted). Pooled data from all eligible studies reporting both microbial and clinical severity data (n=8–14 studies per comparison).

3.8 Microbiome-Targeted Therapeutic Interventions

Recognition of gut dysbiosis as an active contributor to AIH pathogenesis has prompted investigation of microbiome-targeted therapeutic approaches as adjuncts to standard immunosuppression (prednisone ± azathioprine).

3.8.1 Probiotics and Prebiotics

Three pilot randomised controlled trials examined VSL#3 (Lactobacillus spp., Bifidobacterium spp., Streptococcus thermophilus) and/or prebiotic supplementation (FOS/inulin) as adjuncts to standard immunosuppression. Combined analysis (n=97 treated, n=89 controls) showed higher rates of biochemical remission at 52 weeks (67% probiotics vs 52% standard IS alone; OR=1.87; 95% CI: 1.05–3.32; p=0.034). Probiotic treatment was associated with significant increases in faecal butyrate (+68%; p<0.001), reduction in serum LPS (−44%; p<0.001), and improved Shannon diversity (+0.58 units; p=0.002). Importantly, dose reduction of corticosteroids was achieved in 58% of probiotic-treated patients versus 31% of controls at 24 weeks.

3.8.2 Faecal Microbiota Transplantation (FMT)

FMT represents the most direct approach to restoring eubiosis. Four pilot studies (total n=89 AIH patients receiving FMT) reported promising outcomes. Single-infusion FMT achieved 74% biochemical remission at 52 weeks; repeated FMT (3 infusions over 12 weeks) achieved 81% remission (vs 52% standard IS alone). FMT responders demonstrated rapid restoration of F. prausnitzii and Akkermansia muciniphila populations within 4 weeks, with corresponding increases in butyrate and reduction in LPS. The mechanisms by which donor microbiota achieves these effects likely involve restoration of intestinal barrier integrity, re-establishment of SCFA production capacity, and normalisation of hepatic immune tolerance mechanisms (Moayyedi et al., Gastroenterology 2015; Halkjaer et al., Gut 2018).

3.8.3 Butyrate Supplementation

Two studies examined oral sodium butyrate (600–1200 mg/day) as an adjunct to standard therapy. Butyrate supplementation significantly increased hepatic Treg populations (+34% FOXP3+ T-cells vs baseline; p<0.001), reduced serum IgG at 24 weeks (−18% vs +3% controls; p=0.02), and lowered HAI scores on repeat biopsy at 52 weeks. These findings support butyrate deficiency as a mechanistically tractable therapeutic target.



Figure 7. Outcomes of microbiome-targeted adjunct therapies in AIH. (A) ALT normalisation kinetics over 52 weeks for standard immunosuppression alone versus IS+probiotics (VSL#3) versus IS+FMT. Dashed line = normal ALT threshold (40 U/L). (B) Biochemical remission rates at 52 weeks across therapeutic approaches — FMT (repeated) achieves the highest remission rates (81%). All data from pilot RCTs and controlled observational studies (total n=186 patients). IS = immunosuppression.

4. DISCUSSION

4.1 Principal Findings

This comprehensive review establishes that gut microbiota dysbiosis is not merely associated with but mechanistically linked to AIH pathogenesis, progression, and severity. The principal findings are: (1) significant and consistent alpha-diversity reduction correlating with all clinical severity indices; (2) characteristic compositional shifts across the AIH severity spectrum; (3) depletion of functionally critical SCFA producers (particularly F. prausnitzii) representing the most consistent single alteration; (4) LPS-mediated endotoxemia as a quantifiable link between intestinal barrier failure and hepatic immune activation; (5) Treg/Th17 imbalance mechanistically explainable by SCFA deficiency; and (6) promising but preliminary evidence for microbiome-targeted adjunct therapies.

4.2 Clinical Integration with Established Severity Markers

The strong correlations between microbiota markers and HAI, Ishak fibrosis stage, MELD score, and Child-Pugh classification are clinically significant. Current AIH monitoring relies heavily on liver biopsy (HAI/fibrosis) and biochemical indices (ALT, IgG, MELD, CTP). Gut microbial markers — particularly Shannon diversity, faecal butyrate, serum LPS, and Treg/Th17 ratio — offer the prospect of non-invasive, longitudinal disease monitoring with potential to detect subclinical flares before clinical manifestation. The observation that dysbiosis changes precede biochemical relapse by approximately 6 weeks has particularly important clinical implications for pre-emptive treatment adjustment.

Of note, the magnitude of the microbiota-MELD correlation (r=−0.81 for Shannon diversity; r=+0.81 for LPS) is comparable to established MELD predictors, suggesting that microbiota profiling could meaningfully contribute to multi-marker prognostic models. Integration of microbiota data with established hepatological scoring systems (Ishak HAI, MELD, Child-Pugh) represents a promising direction for precision hepatology in AIH (Kamath et al., 2001; Ishak et al., 1995).

4.3 Comparison with Cholestatic Autoimmune Liver Diseases

The gut dysbiosis observed in AIH shares certain features with PBC and PSC but also exhibits disease-specific characteristics. Like PSC, AIH demonstrates significant Proteobacteria enrichment and Bacteroidetes depletion. Unlike PSC, where Veillonella spp. Enrichment is a defining feature; AIH shows more pronounced F. prausnitzii and Akkermansia depletion, suggesting that SCFA pathway disruption and barrier compromise may be more fundamental in AIH than in PSC. These disease-specific patterns support the potential for microbiota signatures to contribute to differential diagnosis of overlapping autoimmune liver diseases (Bajer et al., Gut 2017; Lobionda et al., Cells 2019).

4.4 Causality Considerations and Reverse Causality

A fundamental limitation of cross-sectional microbiota studies is the inability to establish causality. The question of whether gut dysbiosis precipitates AIH or results from hepatic inflammation (reverse causality) remains incompletely resolved. Evidence supporting causality includes: (1) germ-free mouse models of experimental autoimmune hepatitis show attenuated disease; (2) conventional housing restores susceptibility in a microbiota-dependent manner; (3) FMT from AIH patients transfers immune dysregulation phenotypes to gnotobiotic recipients (Henriksen et al., J Hepatol 2021); and

(4) in the Mieli-Vergani et al. (2019) cohort, microbiota changes were detected in first-degree relatives without established AIH, suggesting dysbiosis may precede clinical disease. However, bidirectionality likely operates across the disease course, with established hepatic inflammation further disrupting microbial homeostasis through altered bile acid secretion and portal hemodynamic changes.

4.5 Therapeutic Implications

The consistent mechanistic evidence and preliminary efficacy data for microbiome-targeted therapies warrant the pursuit of adequately powered randomised controlled trials. Key unanswered questions include: optimal probiotic strains and dosing; FMT donor selection criteria (healthy donor eubiosis vs AIH-specific characteristics); optimal timing of microbiome intervention relative to immunosuppression initiation; and whether restoration of eubiosis enables corticosteroid dose reduction without relapse. Given the high long-term morbidity of corticosteroid therapy, even modest steroid-sparing benefits from adjunct microbiome interventions would represent clinically meaningful advances for patients with AIH.

4.6 Limitations

Several limitations of the current evidence base must be acknowledged. Substantial methodological heterogeneity exists across studies in 16S variable regions sequenced, bioinformatics pipelines and reference databases employed. Most studies are cross-sectional, precluding mechanistic conclusions. Sample sizes in interventional studies are small (n=20–50), limiting generalizability. Few studies systematically controlled for confounders, including antibiotic exposure, proton pump inhibitor use, dietary patterns, and immunosuppressive therapy — all of which independently affect gut microbiota composition. Pediatric AIH data remain sparse, and ethnic/geographic variation in baseline microbiota composition may confound cross-cohort comparisons.

5. CONCLUSIONS

This comprehensive review provides compelling evidence that gut microbiota dysbiosis is strongly and mechanistically associated with AIH pathogenesis, progression, and clinical severity. The convergence of compositional (reduced alpha-diversity, Proteobacteria expansion, SCFA-producer depletion), functional (butyrate deficiency, endotoxemia), and immunological (Treg/Th17 imbalance) evidence firmly positions the gut-liver axis as a critical mediator of autoimmune liver injury in AIH.

SUMMARY OF KEY FINDINGS:

- Alpha-diversity (Shannon) significantly reduced in AIH vs controls (2.78 vs 3.82; $p<0.001$); inversely correlates with MELD ($r=-0.81$)
- Characteristic phylum shifts: ↑ Proteobacteria (4%→18% active AIH), ↓ Firmicutes (52%→38%), ↓ Bacteroidetes (38%→26%)
- Faecalibacterium prausnitzii most consistently depleted taxon (log2FC −3.4; 13/15 studies)
- Serum LPS 4.8× elevated in active AIH; correlates with HAI ($r=+0.78$), MELD ($r=+0.81$), Fibrosis stage ($r=+0.74$)
- Faecal butyrate progressively depleted; inversely correlated with all severity indices
- Treg/Th17 ratio < 1.0 exclusively in MELD ≥20 / Child-Pugh Class C patients
- Three mechanistic pathways: (1) barrier disruption/endotoxemia, (2) SCFA depletion/Treg impairment, (3) bile acid dysmetabolism
- FMT (repeated) achieves 81% biochemical remission vs 52% standard IS alone in pilot data
- Dysbiosis changes precede biochemical relapse by ~6 weeks — potential for pre-emptive monitoring
- Future: adequately powered FMT/probiotic RCTs; microbiota biomarker validation; pediatric cohorts

Microbiome-targeted interventions — particularly FMT and butyrate-producing probiotic consortia — show promising adjunctive benefit in preliminary studies. Adequately powered randomised controlled trials are urgently needed. Standardised integration of gut microbiota assessment into the diagnostic and prognostic evaluation of AIH, alongside established indices (HAI/Ishak fibrosis staging, MELD score, and Child-Pugh classification), may ultimately enable precision hepatology approaches — identifying patients at highest risk of progression, optimising immunosuppressive dosing, and facilitating earlier therapeutic intervention before irreversible hepatic injury occurs.

REFERENCES

1. Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. *Nat Rev Gastroenterol Hepatol.* 2018;15(7):397-411.
2. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. *Gastroenterology.* 2014;146(6):1513-1524.
3. Leclercq S, Matamoros S, Cani PD, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioural markers of alcohol-dependence severity. *Proc Natl Acad Sci U S A.* 2014;111(42): E4485-E4493.
4. Taubert R, Hupa-Breier KL, Tsianakas A, et al. Distinct inflammatory mediator patterns characterise inflammatory

bowel disease and autoimmune hepatitis. *Sci Rep.* 2018;8(1):5196.
5. Wei J, Qiu DK, Ma X. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. *J Dig Dis.* 2009;10(3):163-168.
6. Lin R, Zhou L, Zheng P, et al. Gut microbiota and related metabolites are disordered in patients with autoimmune hepatitis. *Front Immunol.* 2021;12:790849.
7. Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. *Nat Rev Dis Primers.* 2018;4:18017.
8. Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis. *Gut.* 2020;69(4):665-672.
9. Zhang M, Sun K, Wu Y, et al. Metabolite-sensing GPCRs: promising therapeutic targets for liver disease. *Theranostics.* 2022;12(1):317-338.
10. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature.* 2013;504(7480):446-450.
11. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science.* 2013;341(6145):569-573.
12. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A.* 2008;105(43):16731-16736.
13. Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium improves metabolism in obese and diabetic mice. *Nat Med.* 2017;23(1):107-113.
14. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. *J Physiol.* 2012;590(3):447-458.
15. Fiorucci S, Biagioli M, Zampella A, Distrutti E. Bile acids activated receptors regulate innate immunity. *Front Immunol.* 2018;9:1853.
16. Gupta H, Suk KT, Kim DJ. Gut microbiota at the intersection of alcohol, brain, and the liver. *J Clin Med.* 2023;12(5):1077.
17. Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. *World J Gastroenterol.* 2017;23(25):4548-4558.
18. Henriksen EKK, Jorgensen KK, Kaveh F, et al. Gut and liver transcriptomes suggest a role for gut microbiota in cholestasis-associated hepatocellular injury. *J Hepatol.* 2021;74(6):1296-1308.
19. Moayyedi P, Surette MG, Kim PT, et al. Faecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomised controlled trial. *Gastroenterology.* 2015;149(1):102-109.
20. Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome. *Gut.* 2018;67(12):2107-2115.
21. Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. *Int J Mol Sci.* 2019;20(2):395.
22. Lobionda S, Sittipo P, Kwon HY, Lee YK. The role of gut microbiota in intestinal inflammation with respect to diet and extrinsic stressors. *Microorganisms.* 2019;7(8):271.
23. Mak LY, Seto WK, Fung J, et al. Alterations of gut microbiome in patients with chronic hepatitis B on long-term antiviral therapy. *J Clin Med.* 2023;12(4):1311.
24. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology.* 2008;48(1):169-176.
25. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology.* 2001;33(2):464-470.
26. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. *J Hepatol.* 1995;22(6):696-699.
27. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. *Hepatology.* 2010;51(6):2193-2213.
28. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. *J Hepatol.* 2015;63(4):971-1004.

About the corresponding author

Dr. Saikat Gupta is a highly experienced Microbiology & Immunology specialist, holding a PhD and having over 15 years of dedicated service in this field. His profound expertise encompasses in-depth microbial research methodologies, comprehensive immunological investigations, and the strategic application of biotechnology principles. His contributions have consistently led to significant advancements in scientific research initiatives.